You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)擬8億港元收購永泰10.0%股權 將完成細胞免疫治療領域的戰略佈局
格隆匯 07-20 20:20

格隆匯7月20日丨華潤醫藥(03320.HK)宣佈,於2021年7月20日,公司全資附屬公司北京醫藥投資管理(BVI)有限公司(作為買方)與Yue Cheng International Capital (HK) Limited、HualidaDevelopment Co. Limited、任小娟及Bei Ni Ltd(作為賣方,統稱"賣方")(其中包括)訂立股份購買協議(,據此,買方有條件同意購買,而賣方有條件同意出售永泰生物製藥有限公司("永泰")合共5145.84萬股普通股(佔永泰截至公吿日期已發行股本總額的10.0%),總代價約為7.9966億港元,相當於每股價格為15.54港元。

公吿稱,細胞免疫治療為未來腫瘤治療的重要發展方針。透過建議收購事項,預期集團能夠完成其於細胞免疫治療領域的戰略佈局。永泰連同其附屬公司(合稱"永泰集團")深耕細胞免疫治療領域約15年,已建立經驗豐富的研發團隊及全方位技術平台,並已獲得核心技術及產品的相關知識產權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account